| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8789984 | Urologic Oncology: Seminars and Original Investigations | 2018 | 13 Pages |
Abstract
LVI is a strong prognostic factor of worse prognosis in patients treated with RC for bladder cancer. This association is strongest in node-negative BC, but it is also in node-positive BC. LVI should be part of all pathological reporting and could provide additional information for treatment-decision making regarding adjuvant therapy after RC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Andrea M.D., Shoji M.D., Beat M.D., Mohammad M.D., David M.D., Kilian M. M.D., Shahrokh F. M.D.,